Diabetes Unit and Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Diabetes Care. 2012 Nov;35(11):2148-55. doi: 10.2337/dc12-0071. Epub 2012 Aug 24.
To test whether safe and effective glycemic control could be achieved in type 1 diabetes using a bihormonal bionic endocrine pancreas driven by a continuous glucose monitor in experiments lasting more than two days and including six high-carbohydrate meals and exercise as challenges to glycemic control.
Six subjects with type 1 diabetes and no endogenous insulin secretion participated in two 51-h experiments. Blood glucose was managed with a bionic endocrine pancreas controlling subcutaneous delivery of insulin and glucagon with insulin pumps. A partial meal-priming bolus of insulin (0.035 units/kg/meal, then 0.05 units/kg/meal in repeat experiments) was administered at the beginning of each meal (on average 78 ± 12 g of carbohydrates per meal were consumed). Plasma glucose (PG) control was evaluated with a reference quality measurement on venous blood every 15 min.
The overall mean PG was 158 mg/dL, with 68% of PG values in the range of 70-180 mg/dL. There were no significant differences in mean PG between larger and smaller meal-priming bolus experiments. Hypoglycemia (PG <70 mg/dL) was rare, with eight incidents during 576 h of closed-loop control (0.7% of total time). During 192 h of nighttime control, mean PG was 123 mg/dL, with 93% of PG values in the range of 70-180 mg/dL and only one episode of mild hypoglycemia (minimum PG 62 mg/dL).
A bihormonal bionic endocrine pancreas achieved excellent glycemic control with minimal hypoglycemia over the course of two days of continuous use despite high-carbohydrate meals and exercise. A trial testing a wearable version of the system under free-living conditions is justified.
在超过两天的实验中,包括 6 餐高碳水化合物餐和运动挑战血糖控制,测试使用基于连续血糖监测仪的双激素仿生内分泌胰腺是否可以实现 1 型糖尿病的安全有效血糖控制。
6 名 1 型糖尿病且无内源性胰岛素分泌的受试者参加了两项 51 小时的实验。使用仿生内分泌胰腺通过胰岛素和胰高血糖素皮下输注来控制血糖,胰岛素泵进行控制。每餐开始时给予胰岛素(0.035 单位/千克/餐,重复实验中为 0.05 单位/千克/餐)的部分餐初剂量(平均每餐消耗 78 ± 12 克碳水化合物)。通过每 15 分钟静脉血的参考质量测量评估血浆葡萄糖(PG)控制。
总体平均 PG 为 158mg/dL,68%的 PG 值在 70-180mg/dL 范围内。较大和较小餐初剂量实验之间的平均 PG 没有显著差异。低血糖(PG <70mg/dL)很少见,在 576 小时闭环控制期间发生了 8 次(总时间的 0.7%)。在 192 小时的夜间控制期间,平均 PG 为 123mg/dL,93%的 PG 值在 70-180mg/dL 范围内,仅发生 1 次轻度低血糖(最低 PG 62mg/dL)。
尽管摄入高碳水化合物餐和运动,双激素仿生内分泌胰腺在两天的连续使用过程中仍实现了出色的血糖控制,且低血糖发生率低。有理由进行一项在自由生活条件下测试可穿戴版本系统的试验。